These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 20544328)

  • 21. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes.
    Oliveira S; van Rooy I; Kranenburg O; Storm G; Schiffelers RM
    Int J Pharm; 2007 Mar; 331(2):211-4. PubMed ID: 17187949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient siRNA delivery with non-viral polymeric vehicles.
    Kim WJ; Kim SW
    Pharm Res; 2009 Mar; 26(3):657-66. PubMed ID: 19015957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.
    Mishra DK; Balekar N; Mishra PK
    Drug Deliv Transl Res; 2017 Apr; 7(2):346-358. PubMed ID: 28050890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic delivery of siRNA: challenging but promising.
    Wang C; Zhou Q
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):19-30. PubMed ID: 22188477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle delivery systems for siRNA-based therapeutics.
    Li J; Xue S; Mao ZW
    J Mater Chem B; 2016 Nov; 4(41):6620-6639. PubMed ID: 32263517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cutting-edge technologies of siRNA delivery and their application in clinical trials.
    Lee K; Jang B; Lee YR; Suh EY; Yoo JS; Lee MJ; Lee JY; Lee H
    Arch Pharm Res; 2018 Sep; 41(9):867-874. PubMed ID: 30136248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivering silence: advancements in developing siRNA therapeutics.
    Novobrantseva TI; Akinc A; Borodovsky A; de Fougerolles A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):217-24. PubMed ID: 18283609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
    Scherman D; Rousseau A; Bigey P; Escriou V
    Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving siRNA bio-distribution and minimizing side effects.
    Scaggiante B; Dapas B; Farra R; Grassi M; Pozzato G; Giansante C; Fiotti N; Grassi G
    Curr Drug Metab; 2011 Jan; 12(1):11-23. PubMed ID: 21222588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of chronic hepatitis B virus infection: a promising approach using small interfering RNA (siRNA).
    Dwivedi M; Misra SP; Misra V; Waikhom RK; Bhatnagar M
    Natl Med J India; 2008; 21(3):123-7. PubMed ID: 19004143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular delivery in vivo of siRNA-based therapeutics.
    Aigner A
    Curr Pharm Des; 2008; 14(34):3603-19. PubMed ID: 19075737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing.
    Wu H; Shi Y; Huang C; Zhang Y; Wu J; Shen H; Jia N
    J Biomater Appl; 2014 Apr; 28(8):1180-9. PubMed ID: 23985535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery strategies for siRNA-mediated gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Akhtar S
    Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
    Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
    Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAMAM dendrimers for siRNA delivery: computational and experimental insights.
    Pavan GM; Posocco P; Tagliabue A; Maly M; Malek A; Danani A; Ragg E; Catapano CV; Pricl S
    Chemistry; 2010 Jul; 16(26):7781-95. PubMed ID: 20496352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.